Reviewing iCoreConnect (NASDAQ:ICCT) and Certara (NASDAQ:CERT)

Certara (NASDAQ:CERT) and iCoreConnect (NASDAQ:ICCT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Certara and iCoreConnect’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Certara	-8.34%	3.43%	2.33%
iCoreConnect	-263.12%	-1,451.73%	-171.32%

Insider and Institutional Ownership

74.0% of Certara shares are owned by institutional investors. Comparatively, 13.4% of iCoreConnect shares are owned by institutional investors. 2.4% of Certara shares are owned by insiders. Comparatively, 59.4% of iCoreConnect shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Certara has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, iCoreConnect has a beta of -0.69, suggesting that its share price is 169% less volatile than the S&P 500.

Valuation & Earnings

This table compares Certara and iCoreConnect”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Certara	$385.15 million	5.82	-$55.36 million	($0.08)	-173.50
iCoreConnect	$11.05 million	0.60	-$15.55 million	($63.20)	-0.05

iCoreConnect has lower revenue, but higher earnings than Certara. Certara is trading at a lower price-to-earnings ratio than iCoreConnect, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Certara and iCoreConnect, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Certara	0	4	4	0	2.50
iCoreConnect	0	0	0	0	0.00

Certara currently has a consensus price target of $15.50, suggesting a potential upside of 11.67%. Given Certara’s stronger consensus rating and higher probable upside, equities analysts plainly believe Certara is more favorable than iCoreConnect.

Summary

Certara beats iCoreConnect on 11 of the 14 factors compared between the two stocks.

About Certara

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

About iCoreConnect

iCoreConnect Inc., a cloud-based software and technology company, provides Health Insurance Portability and Accountability Act (HIPAA) compliant cloud-based software as a service (SaaS) in the United States. The company’s products include iCoreRx, a HIPAA compliant electronic prescription software; iCorePDMP, a solution that checks the patient’s Prescription Drug Monitoring Program (PDMP) history before prescribing controlled substances; iCoreVerify and iCoreVerify+, a HIPAA compliant SaaS solution that automatically retrieves a patients insurance eligibility breakdown to verify their benefits in advance of their appointment and on-demand; iCoreHuddle and iCoreHuddle+, a tool to instantly reveal the revenue potential of each patient; and iCoreCodeGenius, a medical coding reference SaaS solution. It also offers iCoreExchange, a SaaS email solution that allows doctors to send and receive secure email with attachments to and from other healthcare professionals; iCoreCloud, ability to backup their on-premise servers and computers to the cloud; iCoreClaims, for processing and managing claims submitted by policyholders or dental care providers; iCorePay, a patient payment processing solutions for payment and revenue cycle tracking; iCoreSecure, secure SaaS solution that solves privacy concerns in the insurance, real estate, financial and many other industry sectors; and iCoreIT, an IT managed services. The company was formerly known as iMedicor, Inc. and changed its name to iCoreConnect Inc. in June 2017. iCoreConnect Inc. was founded in 1992 and is headquartered in Ocoee, Florida.